Sarah-Meryll Buet

With a background in finance, Meryll started her career in capital markets between London & Paris. Following her passion for sciences, she entered the world of biotechnologies in 2012 with Alkion BioPharma, initially as an investor before later becoming active in managing the development of the company through to its acquisition by Evonik in 2016. Supported by her original team, she created Alkion BioInnovations in 2017 to tackle new high potential markets. Meryll is in charge of the administration, recruitment, business development, fundraising and the global strategy of the company.